BRPI0814060A2 - Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal - Google Patents

Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal

Info

Publication number
BRPI0814060A2
BRPI0814060A2 BRPI0814060-0A2A BRPI0814060A BRPI0814060A2 BR PI0814060 A2 BRPI0814060 A2 BR PI0814060A2 BR PI0814060 A BRPI0814060 A BR PI0814060A BR PI0814060 A2 BRPI0814060 A2 BR PI0814060A2
Authority
BR
Brazil
Prior art keywords
terminal
specific binding
area arranged
binding area
linking peptides
Prior art date
Application number
BRPI0814060-0A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Jeffrey A Ledbetter
William Brady
Original Assignee
Trubion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trubion Pharmaceuticals Inc filed Critical Trubion Pharmaceuticals Inc
Publication of BRPI0814060A2 publication Critical patent/BRPI0814060A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0814060-0A2A 2007-07-06 2008-07-07 Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal BRPI0814060A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94839707P 2007-07-06 2007-07-06
PCT/US2008/069378 WO2009023386A2 (en) 2007-07-06 2008-07-07 Binding peptides having a c-terminally disposed specific binding domain

Publications (1)

Publication Number Publication Date
BRPI0814060A2 true BRPI0814060A2 (pt) 2015-01-06

Family

ID=40351400

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814060-0A2A BRPI0814060A2 (pt) 2007-07-06 2008-07-07 Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal

Country Status (8)

Country Link
US (1) US20090148447A1 (enExample)
EP (1) EP2167130A2 (enExample)
JP (1) JP2010532764A (enExample)
CN (1) CN101990439A (enExample)
AU (1) AU2008287195A1 (enExample)
BR (1) BRPI0814060A2 (enExample)
CA (1) CA2691819A1 (enExample)
WO (1) WO2009023386A2 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
EP2295080A3 (en) 2005-07-25 2011-06-22 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
PE20140196A1 (es) 2007-08-09 2014-03-19 Boehringer Ingelheim Int Anticuerpos anti-cd37
US8629246B2 (en) 2007-09-26 2014-01-14 Ucb Pharma S.A. Dual specificity antibody fusions
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
KR20110044992A (ko) * 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 ＴＧＦ-β 길항제 다중-표적 결합 단백질
WO2010035012A1 (en) * 2008-09-26 2010-04-01 Ucb Pharma S.A. Biological products
EP3281955A1 (en) 2008-10-02 2018-02-14 Aptevo Research and Development LLC Cd86 antagonist multi-target binding proteins
WO2010042904A2 (en) * 2008-10-10 2010-04-15 Trubion Pharmaceuticals, Inc. Tcr complex immunotherapeutics
DK3202898T3 (en) * 2009-11-02 2019-01-14 Univ Washington THERAPEUTIC NUCLEASE COMPOSITIONS AND PROCEDURES
EP2516467A2 (en) 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
SI2519543T1 (sl) 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
MX338932B (es) 2010-03-12 2016-05-06 Immunogen Inc Moleculas de union cd37 y sus inmunoconjugados.
EP3333265B1 (en) 2010-05-14 2020-02-05 Oregon Health & Science University Recombinant hcmv and rhcmv vectors encoding a heterologous antigen isolated from hepatitis b virus and uses thereof
MX2012013490A (es) 2010-05-20 2013-01-29 Ablynx Nv Materiales biologicos relacionados con her3.
US20120189618A1 (en) * 2010-07-16 2012-07-26 Boehringer Ingelheim International Gmbh Superior efficacy of cd37 antibodies in cll blood samples
CN101912599A (zh) * 2010-07-30 2010-12-15 北京凯因科技股份有限公司 重组人白介素15在治疗恶性腹水瘤药物中的应用
US9518132B2 (en) * 2010-11-09 2016-12-13 Altimab Therapeutics, Inc. Protein complexes for antigen binding and methods of use
CN105999293B (zh) 2011-04-01 2019-07-23 德彪发姆国际有限公司 Cd37结合分子及其免疫缀合物
PH12013502441B1 (en) * 2011-04-29 2019-02-08 Univ Washington Therapeutic nuclease compositions and methods
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
US20130068691A1 (en) * 2011-08-05 2013-03-21 Henry John Smith Targeted apheresis for the treatment of rheumatoid arthritis and immune disorders
DK2828284T3 (da) 2012-03-20 2019-06-11 Biogen Ma Inc Jcv-neutraliserende antistoffer
DK2828292T3 (da) 2012-03-20 2019-01-02 Biogen Ma Inc Jcv-neutraliserende antistoffer
KR20150004856A (ko) 2012-04-20 2015-01-13 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 Cd3 결합 폴리펩타이드
US8992915B2 (en) 2012-05-16 2015-03-31 Boehringer Ingelheim International Gmbh Combination of CD37 antibodies with ICE
SI3063275T1 (sl) 2013-10-31 2020-02-28 Resolve Therapeutics, Llc Terapevtske fuzije nukleaza-albumin in postopki
WO2015092024A2 (en) * 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
KR102205348B1 (ko) 2014-07-16 2021-01-20 오레곤 헬스 앤드 사이언스 유니버시티 외인성 항원을 포함하는 인간 시토메갈로바이러스
UA125496C2 (uk) 2015-06-08 2022-04-13 Дебіофарм Інтернаціонал, С.А. Спосіб лікування пацієнта з в-клітинним раком імунокон’югатом, який зв’язується з cd37 разом з антитілом, що зв'язується з cd20
AU2016316758B2 (en) 2015-08-28 2023-02-02 Debiopharm International, S.A. Antibodies and assays for detection of CD37
KR102784293B1 (ko) 2015-09-21 2025-03-20 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
AU2016355468B2 (en) 2015-11-20 2022-12-15 Oregon Health & Science University CMV vectors comprising microRNA recognition elements
AU2017290389B2 (en) 2016-07-01 2024-09-26 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
CN110036112B (zh) 2016-10-18 2024-05-10 俄勒冈健康与科学大学 引发受主要组织相容性复合体e分子限制的t细胞的巨细胞病毒载体
WO2018083633A1 (en) 2016-11-02 2018-05-11 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
WO2018132506A1 (en) 2017-01-10 2018-07-19 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
EP3595721B1 (en) 2017-03-16 2025-07-09 The General Hospital Corporation Chimeric antigen receptors targeting cd37
US10947295B2 (en) 2017-08-22 2021-03-16 Sanabio, Llc Heterodimers of soluble interferon receptors and uses thereof
CA3101790A1 (en) 2018-05-30 2019-12-05 Debiopharm International, S.A. Anti-cd37 immunoconjugate dosing regimens
JP7611705B2 (ja) * 2018-06-22 2025-01-10 ザ ジェネラル ホスピタル コーポレイション Ｃｄ３７及びｃｄ１９を標的とするキメラ抗原受容体
MX2022001882A (es) 2019-08-12 2022-05-30 Aptevo Res & Development Llc Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
WO2022104692A1 (en) * 2020-11-20 2022-05-27 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Engineered antibody, antibody-drug conjugate, and use thereof
EP4255574A1 (en) 2020-12-01 2023-10-11 Aptevo Research and Development LLC Heterodimeric psma and cd3-binding bispecific antibodies
AU2024244733B2 (en) 2023-03-31 2025-12-11 AbelZeta Inc. Bispecific chimeric antigen receptors targeting cd20 and bcma

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4444744A (en) * 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4316885A (en) * 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4818709A (en) * 1983-01-21 1989-04-04 Primus Frederick J CEA-family antigens, Anti-CEA antibodies and CEA immunoassay
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
GB8508845D0 (en) * 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
DE3675588D1 (de) * 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US4932412A (en) * 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5217713A (en) * 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5897861A (en) * 1989-06-29 1999-04-27 Medarex, Inc. Bispecific reagents for AIDS therapy
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5023264A (en) * 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5023263A (en) * 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5221670A (en) * 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5120842A (en) * 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) * 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) * 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) * 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
DE69233528T2 (de) * 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
PT1696031E (pt) * 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5177203A (en) * 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US6066718A (en) * 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5480988A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5411967A (en) * 1992-10-13 1995-05-02 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5504091A (en) * 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
WO1995009917A1 (en) * 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
US5391730A (en) * 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5385908A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5385909A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5385910A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5389639A (en) * 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US6380369B1 (en) * 1994-01-27 2002-04-30 Human Genome Sciences, Inc. Human DNA mismatch repair proteins
US5945273A (en) * 1997-06-03 1999-08-31 Human Genome Sciences, Inc. Human oxalyl-coa decarboxylase
US5888773A (en) * 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
PT807183E (pt) * 1994-08-26 2001-05-31 Aventis Pharma Gmbh Terapia genetica de doencas induzidas pelo sistema imunitario com auxilio de uma substancia reguladora do ciclo celular especifica das celulas
US6380169B1 (en) * 1994-08-31 2002-04-30 Isis Pharmaceuticals, Inc. Metal complex containing oligonucleoside cleavage compounds and therapies
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5491231A (en) * 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US6383814B1 (en) * 1994-12-09 2002-05-07 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US6410690B1 (en) * 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5866330A (en) * 1995-09-12 1999-02-02 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
US6379966B2 (en) * 1999-02-26 2002-04-30 Mirus Corporation Intravascular delivery of non-viral nucleic acid
DE19613691A1 (de) * 1996-04-05 1997-10-09 Boehringer Ingelheim Int Arzneimittel für die Behandlung von Tumorerkrankungen
US5922845A (en) * 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US5846948A (en) * 1996-08-30 1998-12-08 Arch Development Corporation Herpes simplex virus ORF P is a repressor of viral protein synthesis
GB9618477D0 (en) * 1996-09-04 1996-10-16 Univ Leeds Gene therapy
US5858753A (en) * 1996-11-25 1999-01-12 Icos Corporation Lipid kinase
DE19651443A1 (de) * 1996-12-11 1998-06-18 Hoechst Ag Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme
EP0860445A1 (en) * 1997-02-18 1998-08-26 Hoechst Aktiengesellschaft New nucleotide sequences for the cell cycle regulated expression of structural genes
ATE241993T1 (de) * 1997-03-11 2003-06-15 Aeterna Lab Inc Zubereitungen zur tumorbehandlung enthaltend hai- knorpelextrakte und antineoplastische mittel
CA2284211A1 (en) * 1997-03-20 1998-09-24 University Of Washington Solvent for biopolymer synthesis, solvent microdroplets and methods of use
US6384203B1 (en) * 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US6217900B1 (en) * 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6383746B1 (en) * 1997-10-23 2002-05-07 The United States Of America As Represented By The Department Of Health And Human Services Functional promoter for CCR5
US6383811B2 (en) * 1997-12-30 2002-05-07 Mirus Corporation Polyampholytes for delivering polyions to a cell
US6383481B1 (en) * 1998-03-30 2002-05-07 Japan Immunoresearch Laboratories Co., Ltd. Method for transplantation of hemopoietic stem cells
EP1073721B1 (en) * 1998-04-22 2005-08-31 Genvec, Inc. Efficient purification of adenovirus
US7052872B1 (en) * 1999-06-22 2006-05-30 Immunomedics, Inc. Bi-specific antibodies for pre-targeting diagnosis and therapy
US6383794B1 (en) * 1998-08-24 2002-05-07 Uab Research Foundation Methods of producing high titer recombinant adeno-associated virus
US6197294B1 (en) * 1998-10-26 2001-03-06 Neurotech S.A. Cell surface molecule-induced macrophage activation
US6380371B1 (en) * 1998-12-10 2002-04-30 The Regents Of The University Of California Endoglycan: a novel protein having selectin ligand and chemokine presentation activity
US6383753B1 (en) * 1999-03-31 2002-05-07 Regents Of The University Of Michigan Yeast mammalian regulators of cell proliferation
AU4476600A (en) * 1999-04-22 2000-11-10 Vanderbilt University Polymeric encapsulation system promoting angiogenesis
US6380382B1 (en) * 1999-06-30 2002-04-30 Millennium Pharmaceuticals, Inc. Gene encoding a protein having diagnostic, preventive, therapeutic, and other uses
US6380362B1 (en) * 1999-12-23 2002-04-30 Genesis Research & Development Corporation Ltd. Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use
EP1257197A4 (en) * 2000-02-25 2008-07-16 Health Research Inc PROCESS FOR TRANSDERMAL SAMPLING OF ANALYTES
EP1284752A4 (en) * 2000-04-26 2004-08-18 Elusys Therapeutics Inc BISPECIFIC MOLECULES AND USES THEREOF
US7560534B2 (en) * 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
US20020025317A1 (en) * 2000-07-20 2002-02-28 Schering Ag Bispecific monoclonal antibodies to IL-12 and IL-18
DE50112379D1 (de) * 2000-08-11 2007-05-31 Univ Ruprecht Karls Heidelberg Fv-konstrukte mit beeinflussbarer affinitat zu einer zu bindenden substanz
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
HUP0303428A2 (hu) * 2001-03-07 2004-01-28 Merck Patent Gmbh. Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez
US20030008923A1 (en) * 2001-06-01 2003-01-09 Wyeth Antineoplastic combinations
US20030026780A1 (en) * 2001-07-18 2003-02-06 Hood Leroy E. Innate immunity mediated methods of treating pathological conditions
IL161418A0 (en) * 2001-10-15 2004-09-27 Immunomedics Inc Direct targeting binding proteins
AU2003209446B2 (en) * 2002-03-01 2008-09-25 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US7332580B2 (en) * 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US7332585B2 (en) * 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
WO2004058191A2 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
CN1279056C (zh) * 2003-06-06 2006-10-11 马菁 肿瘤相关抗原sm5－1的特异性抗体及其应用
US6864837B2 (en) * 2003-07-18 2005-03-08 Ems Technologies, Inc. Vertical electrical downtilt antenna
WO2005018671A1 (ja) * 2003-08-21 2005-03-03 Kyowa Hakko Kogyo Co., Ltd. 癌転移阻害剤
WO2005047337A1 (en) * 2003-11-13 2005-05-26 Hanmi Pharmaceutical Co., Ltd. A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
US20060008415A1 (en) * 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
CA2578613A1 (en) * 2004-08-11 2007-01-25 Trubion Pharmaceuticals, Inc. Binding domain fusion proteins
WO2006117782A2 (en) * 2005-05-04 2006-11-09 Quark Pharmaceuticals, Inc. Recombinant antibodies against cd55 and cd59 and uses thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
EP2158318A2 (en) * 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto

Also Published As

Publication number Publication date
CA2691819A1 (en) 2009-02-19
WO2009023386A3 (en) 2009-11-19
US20090148447A1 (en) 2009-06-11
EP2167130A2 (en) 2010-03-31
WO2009023386A2 (en) 2009-02-19
JP2010532764A (ja) 2010-10-14
CN101990439A (zh) 2011-03-23
AU2008287195A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
CY2020009I1 (el) Δεσμευτικοι παραγοντες σκληροστινης
CY2018001I2 (el) Πρωτεϊνες συνδεσης αντιγονου υποδοχεα a il-17
BRPI0922505A2 (pt) proteínas de ligação a receptor cgrp humano
EP2093287A4 (en) PEPTIDE BINDER IGG
BRPI0907363A2 (pt) Métodos e composições relativos a peptídeos e proteínas com elementos de c-terminal
EP1961761A4 (en) Novel peptide compound
BRPI0818288A2 (pt) Proteínas conjugadas e peptídeos.
DK2035447T3 (da) Polypeptid
IL221062B (en) Stitched polypeptides
GB2449354B (en) Binding protein
DK2171053T3 (da) Natriuretiske polypeptider
ZA201004133B (en) Antigen binding proteins
EP1957094A4 (en) CALCIUM-BINDING PEPTIDES
EP2017283A4 (en) Peptides
DE112007001538A5 (de) Kontaktloser Schalter
GB0611116D0 (en) Proteins
EP2101804A4 (en) PROANGIOGENIC PEPTIDES
BRPI0914557A2 (pt) proteína de ligação de biotina modificada
ATE530564T1 (de) Peptid-komplement-konjugate
GB0601976D0 (en) Proteins
GB0725201D0 (en) Peptide fusion proteins
DK1968623T3 (da) Bacteriocin-inducer-peptider
BRPI0815379A2 (pt) peptídeos modificados tendo efeitos intesificadores de toxina
GB0620735D0 (en) Proteins
GB0618748D0 (en) Peptide

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B25B Requested transfer of rights rejected

Owner name: TRUBION PHARMACEUTICALS, INC. (US)